ArticlePloS one2019
In vivo clearance of nanoparticles by transcytosis across alveolar epithelial cells.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- The eATP/P2×7R Axis Drives Quantum Dot-Nanoparticle Induced Neutrophil Recruitment in the Pulmonary Microcirculation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Toward Standardization of a Lung New Approach Model for Toxicity Testing of Nanomaterials.Nanomaterials (Basel, Switzerland) · 2024Article
- Determinants and mechanisms of inorganic nanoparticle translocation across mammalian biological barriers.Archives of toxicology · 2023Review
- A toxicological profile of silica nanoparticles.Toxicology research · 2022Review
- Caveolin-initiated macropinocytosis is required for efficient silica nanoparticles' transcytosis across the alveolar epithelial barrier.Scientific reports · 2022Article
- Analysis of the Aerosol Generated from Tetrahydrocannabinol, Vitamin E Acetate, and Their Mixtures.Toxics · 2022Article
- Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021Review
- Cytotoxicity and DNA damage evaluation of TiOToxicology research · 2021Article
- Bacterial extracellular vesicles isolated from organic dust induce neutrophilic inflammation in the lung.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- Understanding the in vivo Fate of Advanced Materials by Imaging.Advanced functional materials · 2020Article
- Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.ACS applied materials & interfaces · 2020Article
- Nanoparticle delivery in vivo: A fresh look from intravital imaging.EBioMedicine · 2020Review
- Active transcytosis and new opportunities for cancer nanomedicine.Nature materials · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Nanoparticles in polluted air or aerosolized drug nanoparticles predominantly settle in the alveolar lung. Here, we describe a novel, highly effective pathway for the particles to cross the alveolar epithelium and reach the lymph and bloodstream. Amorphous silica nanoparticles, suspended in perfluorocarbon, were instilled into the lungs of mice for intravital microscopy. Particles formed agglomerates that settled on the alveolar wall, half of which were removed from the lung within 30 minutes. TEM histology showed agglomerates in stages of crossing the alveolar epithelium, in large compartments inside the epithelial cells and crossing the basal membrane into the interstitium. This pathway is consistent with published kinetic studies in rats and mice, using a host of (negatively) charged and polar nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.